Tuberculosis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Class of Drugs (First Line Drugs, Second Line Drugs), By TB (TB, Multi-Drug Resistance TB), By Route Of Administration (Oral, Parental), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Region    

Tuberculosis Treatment Market size was valued at US$ 1.7 billion in 2023 and is poised to grow at a CAGR of 6.1% from 2024 to 2030. Tuberculosis is an infectious disease usually caused by the bacteria Mycobacterium tuberculosis. TB usually affects the lungs and transmits to direct contact with the sputum of the infected person. The global tuberculosis treatment market is projected to grow at significant rates owing to an increase in the prevalence of immunosuppressant diseases such as HIV around the globe. HIV-infected patients are very susceptible to being infected by TB. According to UNAIDS statistics, about 36.7 million people were living with HIV in 2016. Companies operating in the global market focus on new product developments and launches to maximize their share in the market. Furthermore, collaborations and acquisitions are also key strategies adopted by the companies to strengthen their position in the global market. For instance, in August 2017, Johnson & Johnson Services Inc. entered into a partnership with the Institute of Microbial Technology to accelerate the discovery of novel treatments for tuberculosis.

The rising number of medicine recalls is a key stumbling block to the market's expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis' drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug. Another element limiting the market's growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity. Although advanced technologies and the development of novel therapies are expected to reduce the time it takes to treat tuberculosis, most cases can take up to 6 months to treat with currently available drugs. Despite existing medicines and ongoing TB treatment drug advances, there is a constant need to increase patients' access to appropriate TB medicines, particularly in the areas of MDR TB and pediatric TB.